Biotech Hangout cover image

Episode 76

Biotech Hangout

00:00

Disappointing Results of F4 Cirrhosis Nash Study and Impact on Stock

The chapter discusses the disappointing results of a study on F4 cirrhosis Nash and the potential negative impact on the stock. They mention concerns about the timeline for a larger phase 3 study and the fear surrounding the F2-3 space.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app